NUMD — Nu-Med Plus Income Statement
0.000.00%
- $2.04m
- $2.24m
- 11
- 53
- 18
- 16
Annual income statement for Nu-Med Plus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.99 | 0.83 | 0.132 | 0.121 | 0.063 |
| Operating Profit | -1.99 | -0.83 | -0.132 | -0.121 | -0.063 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.01 | -0.83 | -0.13 | -0.126 | -0.068 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.01 | -0.83 | -0.13 | -0.126 | -0.068 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.01 | -0.83 | -0.13 | -0.126 | -0.068 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.01 | -0.83 | -0.13 | -0.126 | -0.068 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.037 | -0.011 | -0.002 | -0.002 | -0.001 |